IcareLife

06/07/2025

One gene in the right place could change the future of TDT Thalassemia in a single day.”

06/07/2025

SMA patient treated with Icare gene therapy,Just in 19 days ,great improvement in the movement.Amazing !

14/06/2025

New hope for SMA type 1 and 2 ,icare gene therapy potentially can cure it

31/05/2025

New hope for SMA type 1 and Type 2 patient ,a new gene therapy vesemnogene to treat SMA ,this gene therapy provide potential cure if treated early .
The phase 1 clinical result is very promising.
https://www.medrxiv.org/content/10.1101/2025.04.13.25325764v2.full.pdf.
In order to benefit more SMA to treated and improve their quality of life and to avoid lose their motor neurons resulting muscle weakness.
We introduce early access program to invite more SMA to be treated .anyone interested on EAP ,please join our SMA concern group https://chat.whatsapp.com/HK5Rjk8MJhE8qJe5eQ4Ga9
Please also contact us rickykoh@icare.com.my or icarebiotech@gmail.com
Whatsapp:+60102323818

30/05/2025

New hope for Blood transfusion dependent Thalassemia patient

New hope for blood transfusion dependent Thalassemia patient ,Icare gene therapy provide a cure to this disease .The treated patient will no longer require any blood transfusion for the rest of their life .This gene therapy is very safe ,high efficacy and affordable.Many patients is cured under this therapy.
We are providing this gene therapy treatment through EAP early access programs to benefit more TDT patients to reduce their cost of treatment and improve their quality of life .
Any one interested in this treatment,please contact us at email:icarebiotech@gmail.com
WhatsApp:+60102323818
Please join our Thalassemia Concern Group https://chat.whatsapp.com/IfoxFWRn4ELFsRmSm9iFo5
Our Medical consultation Dr Lim will answer your question and concern .
We warmly invite you to join us in reducing dependence on blood transfusions and enhancing quality of life through this groundbreaking gene therapy, Vebeglogene autotemcel.”
Major
Thalassemia
vietnam
Japan
Hong kong
Korea
Taiwan
UK /Europe

28/05/2025

New hope for blood transfusion dependent Thalassemia patient ,Icare gene therapy provide a cure to this disease .The treated patient will no longer require any blood transfusion for the rest of their life .This gene therapy is very safe ,high efficacy and affordable.Many patients is cured under this therapy.
We are providing this gene therapy treatment through EAP early access programs to benefit more TDT patients to reduce their cost of treatment and improve their quality of life .
Any one interested in this treatment,please contact us at email:icarebiotech@gmail.com
WhatsApp:+60102323818
Please join our Thalassemia Concern Group https://chat.whatsapp.com/IfoxFWRn4ELFsRmSm9iFo5
Our Medical consultation Dr Lim will answer your question and concern .
We warmly invite you to join us in reducing dependence on blood transfusions and enhancing quality of life through this groundbreaking gene therapy, Vebeglogene autotemcel.”
Major
Thalassemia
vietnam
Japan
Hong kong
Korea
Taiwan
UK /Europe

08/05/2025

14/03/2025

The SMA after treated with gene therapy,can crawl and stand with support .This is amazing result .
Look at the video attached.

What is SPINA MUSCULAR ATROPHY ?
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that results in the loss of motor neurons and progressive muscle wasting. It is usually diagnosed in infancy or early childhood and if left untreated it is the most common genetic cause of infant death.It may also appear later in life and then have a milder course of the disease. The common feature is progressive weakness of voluntary muscles, with arm, leg and respiratory muscles being affected first. Associated problems may include poor head control, difficulties swallowing, scoliosis, and joint contractures.

1.Type I SMA (Werdnig–Hoffmann) has clinical onset within the first three months of life, usually leading to respiratory failure and death by two years of age.
2.The onset of Type II SMA is 6-18 months of age, and the affected children may sit independently but cannot stand or walk, with 70% surviving beyond 25 years of age.
3.Patients with Type III SMA (Kugelberg– Welander), with the onset at ≥18 months, have difficulty climbing stairs and running and often have a normal lifespan.
4.Type IV SMA or adult-onset SMA is described with slow progression of muscle weakness beginning at around 30 years of age, and with no reduction in life expectancy.
If you need more information please contact at support@icare.com.my

什么是脊髓性肌萎缩症？
脊髓性肌萎缩症（Spinal Muscular Atrophy，简称SMA）是一种罕见的神经肌肉疾病，会导致运动神经元丧失和进行性肌肉萎缩。此病通常在婴儿期或幼儿期被确诊，若未及时治疗，是导致婴儿死亡最常见的遗传性病因。该病也可能在成年后发病，且病情发展较为温和。其共同特征是自主肌肉的进行性无力，手臂、腿部及呼吸肌往往最先受到影响。相关症状可能包括头部控制能力差、吞咽困难、脊柱侧弯以及关节挛缩。

脊髓性肌萎缩症（SMA）根据发病年龄和严重程度分为以下类型：
1. **I型SMA（韦德尼希-霍夫曼病）**：临床发病于出生后三个月内，通常因呼吸衰竭在2岁前致命。
2. **II型SMA**：发病年龄为6-18个月，患儿可独坐但无法站立或行走，约70%的患者可存活至25岁以上。
3. **III型SMA（库格尔贝格-韦兰德病）**：发病于18个月及以上，表现为爬楼梯和奔跑困难，但寿命通常不受影响。
4. **IV型SMA（成人型）**：约30岁左右缓慢出现肌无力症状，疾病进展较缓，预期寿命与常人无异。
欲知详情请联系support@icare.com.my

18/02/2025

What is SPINA MUSCULAR ATROPHY ?
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that results in the loss of motor neurons and progressive muscle wasting. It is usually diagnosed in infancy or early childhood and if left untreated it is the most common genetic cause of infant death.It may also appear later in life and then have a milder course of the disease. The common feature is progressive weakness of voluntary muscles, with arm, leg and respiratory muscles being affected first. Associated problems may include poor head control, difficulties swallowing, scoliosis, and joint contractures.

1.Type I SMA (Werdnig–Hoffmann) has clinical onset within the first three months of life, usually leading to respiratory failure and death by two years of age.
2.The onset of Type II SMA is 6-18 months of age, and the affected children may sit independently but cannot stand or walk, with 70% surviving beyond 25 years of age.
3.Patients with Type III SMA (Kugelberg– Welander), with the onset at ≥18 months, have difficulty climbing stairs and running and often have a normal lifespan.
4.Type IV SMA or adult-onset SMA is described with slow progression of muscle weakness beginning at around 30 years of age, and with no reduction in life expectancy.
If you need more information please contact at support@icare.com.my

什么是脊髓性肌萎缩症？
脊髓性肌萎缩症（Spinal Muscular Atrophy，简称SMA）是一种罕见的神经肌肉疾病，会导致运动神经元丧失和进行性肌肉萎缩。此病通常在婴儿期或幼儿期被确诊，若未及时治疗，是导致婴儿死亡最常见的遗传性病因。该病也可能在成年后发病，且病情发展较为温和。其共同特征是自主肌肉的进行性无力，手臂、腿部及呼吸肌往往最先受到影响。相关症状可能包括头部控制能力差、吞咽困难、脊柱侧弯以及关节挛缩。

脊髓性肌萎缩症（SMA）根据发病年龄和严重程度分为以下类型：
1. **I型SMA（韦德尼希-霍夫曼病）**：临床发病于出生后三个月内，通常因呼吸衰竭在2岁前致命。
2. **II型SMA**：发病年龄为6-18个月，患儿可独坐但无法站立或行走，约70%的患者可存活至25岁以上。
3. **III型SMA（库格尔贝格-韦兰德病）**：发病于18个月及以上，表现为爬楼梯和奔跑困难，但寿命通常不受影响。
4. **IV型SMA（成人型）**：约30岁左右缓慢出现肌无力症状，疾病进展较缓，预期寿命与常人无异。
欲知详情请联系support@icare.com.my

18/02/2025

SMA patient treated with icare vesemnogene gene therapy, ,the bayi can seat independently in 1.50 months and crawl in 2.5 months .This treatment is available in Malaysia
SMA患者接受icare基因治療，，孩子可在1.5個月內獨立坐下，2.5個月內爬行。

23/09/2021